Sectors
GLPG
Galapagos N.V.
27.98
1 x 20.48
1 x 35.21
bid
ask
+
0.47
1.71%
11:58 AM
timesize
| Ytd | -14.43% | |
| 1y | -3.08% |
27.50
day range
28.09
24.74
52 week range
37.78
| Open | 27.50 | Prev Close | 27.51 | Low | 27.50 | High | 28.09 | Mkt Cap | 1.84B |
| Vol | 2.38K | Avg Vol | 187.56K | EPS | 8.71 | P/E | 3.21 | Forward P/E | -26.56 |
| Beta | 0.25 | Short Ratio | 6.95 | Inst. Own | 22.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 30.32 | 200-d Avg | 32.15 | 1yr Est | 27.23 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-10 | 2026-06 | -0.97 | N/A | N/A | N/A |
| 2026-05-06 | 2026-03 | -1.27 | 0.25 | 1.52 | 119.69% |
| 2026-02-23 | 2025-12 | 1 | 16.38 | 15.38 | 1538.00% |
| 2025-11-05 | 2025-09 | -0.2 | -3.59 | -3.39 | -1696.35% |
| 2025-07-23 | 2025-06 | -0.67 | -1.89 | -1.22 | -182.27% |
| 2025-04-23 | 2025-03 | -0.23 | -2.47 | -2.24 | -973.91% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-02-25 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
| 2025-11-07 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
| 2025-10-22 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
| 2025-10-21 | Leerink Partners | Upgrade | Market Perform | Outperform |
| 2025-02-14 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
| 2025-01-23 | Barclays | Downgrade | Equal-Weight | Underweight |
Profile
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Gilead Sciences Inc | 16.71M | 463.30M | 25.35% |
| 2025-12-30 | Tang Capital Management, LLC | 3.92M | 108.74M | 5.95% |
| 2025-12-30 | Madison Avenue Partners, LP | 2.21M | 61.37M | 3.36% |
| 2025-12-30 | EcoR1 Capital, LLC | 1.67M | 46.23M | 2.53% |
| 2025-12-30 | Ameriprise Financial, Inc. | 1.45M | 40.24M | 2.20% |
| 2025-12-30 | Prosight Management, Lp | 1.07M | 29.79M | 1.63% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-02-27 | Columbia Funds Series Trust-Columbia Overseas Value Fund | 714.75K | 19.82M | 1.08% |
| 2025-12-30 | Columbia Fd.s Varbl Series TRT II-Columbia Varbl PORT. - Overseas Core | 385.91K | 10.70M | 0.59% |
| 2026-03-30 | iShares Trust-iShares Core MSCI EAFE ETF | 314.77K | 8.73M | 0.48% |
| 2026-03-30 | iShares Trust-iShares Biotechnology ETF | 272.46K | 7.56M | 0.41% |
| 2026-03-30 | iShares Trust-iShares MSCI EAFE Small-Cap ETF | 130.42K | 3.62M | 0.20% |
| 2025-12-30 | Segall Bryant & Hamill Trust-SBH Small Cap Value Fund | 94.15K | 2.61M | 0.14% |